Loading stock data…
DarioHealth Corp. (DRIO)
$7.79+0.32 (+4.28%)
Market ClosedLast close Jul 24
DarioHealth Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DarioHealth Corp. in the Healthcare sector is trading at $7.79 with a market capitalization of $56M. Wall Street consensus targets $18.50 (4 analysts), implying a +137.5% move over the next 12 months. The stock is currently near its 52-week low of $5.84, remaining 21.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +137.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.58M↑ | $5.23M↑ | $5.01M↓ | $5.37M↓ | $6.75M |
| Gross Profit | $3.20M↑ | $2.80M↓ | $3.02M↑ | $2.96M↓ | $3.88M |
| Operating Income | -$7.31M↑ | -$8.56M↑ | -$9.48M↓ | -$9.20M↑ | -$9.41M |
| Net Income | -$8.25M↑ | -$9.03M↑ | -$10.47M↑ | -$12.99M↓ | -$9.23M |
Peer Comparison
JNJUNHPFE
Fundamentals
DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$55.94M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-65.30%
Volume
Today's trading volume
2,791
Recent News
DarioHealth (DRIO) Moves 12.9% Higher: Will This Strength Last?
DarioHealth (DRIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Fortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care Platform
DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced another Fortune 50 employer has selected Dario to provide its integrated digital cardiometabolic care platform for employees living with diabetes and/or hypertension. The program will be available to more than 100,000 eligible employees and is expected to launch in Fall 2026. "Winning another Fortune 50 employer underscores the growing recognition that integrated chronic condition management delivers better outcomes than treating each condition independently, resulting in clinically significant outcomes and economic impact," said Erez Raphael, Chief Executive Officer of Dario.
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State
DarioHealth (DRIO) Upgraded to Buy: Here's Why
DarioHealth (DRIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DarioHealth Corp (DRIO) Q1 2026 Earnings Call Highlights: Navigating Growth and Strategic ...
DarioHealth Corp (DRIO) showcases revenue growth and strategic partnerships amid operational challenges and future opportunities.